Our Speakers
Discover the pioneering minds headlining the Borealis Psychedelic Science Summit 2025. Below, you’ll find our growing roster of experts. Click on each speaker to learn more about their background, their summit topic, and the insights they’ll share in Stockholm. We’ll be updating this page as more speakers are confirmed, so check back often.
Dr. Christoffer Timmermann, researcher at University College London, leads the DMT Research Group exploring psychedelics’ effects on brain and mind.
Dr. David Nutt, Prof. of Neuropsychopharmacology at Imperial College, pioneers breakthroughs from GABA to psychedelics.
Dr. Leor Roseman, researcher at University of Exeter, merges neuroscience, anthropology, and conflict resolution in psychedelic studies.
Dr. Maria Beckman, psychologist at Karolinska, researches psilocybin therapies and therapist–patient dynamics in clinical trials.
Josh Hardman, founder of Psychedelic Alpha, offers data-driven insights on psychedelics, spanning business, policy, and research.
Dr. Julie Holland, NYT-bestselling psychiatrist and MAPS advisor, pioneers MDMA and cannabis-assisted therapies.
Dr. Gerhard Gründer, psychiatrist at CIMH Mannheim, pioneers advanced imaging and psychedelic research in severe mental disorders.
Dr. Paul Liknaitzky, leading psychedelic researcher at Monash, spearheads transformative clinical trials and novel therapies in Australia.